Abstract:Antifungal agents for the treatment of Candida albicans infections are limited. We recently discovered a novel antifungal small molecule, SM21, with promising in vivo activity. Herein, we employed the newly developed C. albicans haploid toolbox to uncover the mechanism of action of SM21. Comprehensive RNA-Seq analyses of the haploid susceptible GZY803 strain revealed significant gene expression changes related to mitochondria when exposed to SM21. Mitochondrial structure visualization and measurement of ATP generation, reactive oxygen species (ROS) levels, and the antioxidant potential of SM21-treated and untreated GZY803, mitochondrial structure defective haploid mutant (dnm1Δ), and wild-type diploid SC5314 strains confirmed defects in mitochondria. Exploiting the advantage of C. albicans haploids as a single ploidy model, we further exposed GZY803 to repetitive treatments of SM21 in order to generate resistant mutants. Three colonies designated S3, S5 and S6, which displayed resistance to SM21, were isolated. All resistant strains exhibited enhanced transcriptomic responses for peptide and protein metabolism and secreted aspartate proteases (SAPs) activity under SM21 treatment compared to the parent strain GZY803. Consistently, supplementing the resistant strains, GZY803, and SC5314 with peptone, a form of digested peptides, decreased susceptibility to SM21. The present study demonstrates the usefulness of haploid C. albicans model in antifungal drug discovery. The findings will be invaluable to develop SM21 as a novel antifungal agent, which will benefit millions of patients suffering from Candida infections.

[Cloning and Expression of the Mutant 14Alpha-Demethylase Containing the Alteration of H310D in Candida Albicans and the Preliminary Study on Its Functions].

Comparative Study on the Partial ERG11 Gene Sequence Between the Yeast and Hyphal Forms of Candida Albicans

Expression and Detection the Enzyme Activity of the Wild and Mutation Type of CYP51 Protein of Candida albicans

Use of Haploid Model of Candida Albicans to Uncover Mechanism of Action of a Novel Antifungal Agent.

Identification of Y118 amino acid residue in Candida albicans sterol 14alpha-demethylase associated with the enzyme activity and selective antifungal activity of azole analogues.

The Point Mutation of Cytochrome P-450 Lanosterol 14-Α Demethylase ERG11 Gene in Fluconazole-resistant Candida Albicans

Drug susceptibilities of yeast cells are affected when expressing mutant Candida albicans drug resistance protein.

[Cloning and Sequencing of the GTP Cyclohydrolase I Function Region of Azole Target Enzyme Gene in Artificially Induced Resistant Candida Albicans].

Cloning and Functional Identification of 14Α-Demethylase Genes (ERG11) from Two Different Candida Haemulonii Strains with Degenerate PCR Combined with RACE

Study on the Relationship Between K143Q Amino Acid Substitution in 14Α-Demethylase and Fluconazole Resistance to Candida Albicans

Mutation Hotspot of CYP51 of Candida Albicans to Azole Resistance

Analysis of gene structure, cloning and expression of cyp51 from Ustilago maydis]

Association of T916c (y257h) Mutation in Candida Albicans Erg11 with Fluconazole Resistance

Cloning and Identification of Genes Related with Morphogenesis of Candida albicans.

Evolutionary Trace Analysis of CYP51 Family: Implication for Site-Directed Mutagenesis and Novel Antifungal Drug Design

Erg11 Mutations Associated with Azole Resistance in Clinical Isolates of Candida Albicans.

Characterization of an Allosteric Inhibitor of Fungal-Specific C-24 Sterol Methyltransferase to Treat Candida Albicans Infections

Erg 11 mutations associated with azole resistance in clinical isolates of Candida albicans Running title : Erg 11 mutations in Candida albicans

Expression and Enzymatic Analysis of the Human Cytochrome CYP1A2 in Saccharomyces cerevisiae

In vitro fluconazole susceptibility of 1,903 clinical isolates of Candida albicans and the identification of ERG11 mutations.

The relationship between ERG11 gene mutation of Candida albicans and fluconazole-resistance